Zinc oxide nanoparticles boost tuberculosis drugs against resistant strains

Tuberculosis (TB) remains a major global health threat, and the rise of drug-resistant strains has made the disease harder to control. Current TB treatments are long and often cause severe side effects, which can lead to poor patient compliance and treatment failure. In response to these challenges, researchers led by Sasmita Nayak examined whether metal-based nanoparticles could improve TB therapy. Prior work had suggested that such nanoparticles can help manage drug-sensitive TB when used alongside anti-TB drugs, but their effect on drug-resistant TB was not yet established. Nayak and colleagues specifically tested Zinc Oxide Nanoparticles (ZnO nanoparticles, ZnONPs, 40 nm) for their ability to kill both drug-susceptible and multidrug-resistant Mycobacterium tuberculosis (Mtb) when combined with anti-TB drugs. The team set out to understand not only whether ZnONPs enhance bactericidal activity, but also how they act at a molecular level, focusing on a critical protein-processing event required for Mtb survival.

The study found that ZnONPs interfere with the formation of active SufB protein by inhibiting SufB splicing, an essential process for Mycobacterium tuberculosis survival. Multiple laboratory techniques supported this mechanism and the bactericidal effects. TEM and UV-visible spectroscopy identified interactions between the nanoparticles and protein, while SEM visualized extensive membrane damage in H37Rv and multidrug-resistant (MDR) Mtb cells. The team used Alamar blue assay and spread plate method to determine minimum inhibitory concentration and minimum bactericidal concentration of ZnONPs against the H37Rv strain and MDR Mtb isolates. In vitro experiments showed a particular combination with ZnONPs that reduced the effective doses of anti-TB drugs needed to act on both H37Rv and MDR Mtb isolates. To link the effect to SufB splicing, the researchers performed Alamar blue assay in a SufB intein-less microbe, Mycobacterium smegmatis. Finally, a similar drug-plus-ZnONPs combination in infected mice reduced mycobacterial load, lessened inflammation in the spleen & lungs, and protected against Mtb induced splenomegaly.

These results suggest ZnONPs could serve as a potent additive to existing anti-TB regimens for both drug-susceptible and drug-resistant tuberculosis. By targeting SufB splicing, ZnONPs hit a critical vulnerability in Mtb biology that appears to both damage cell membranes and disrupt essential protein activation. The combination reduced the amount of anti-TB drug required in laboratory tests and produced measurable benefits in a mouse infection model, including lower bacterial counts and reduced organ inflammation. If these findings hold up in further studies, using ZnONPs alongside standard therapy could help address several practical problems in TB care: it could lower drug doses, potentially reduce toxicity, shorten or simplify treatment courses, and improve patient compliance. The work described by Sasmita Nayak points toward a complementary strategy that adds a nanoparticle component to antibiotic regimens rather than replacing existing drugs outright.